Morningstar

ATyr Pharma's Lead Program Misses Main Endpoint in Phase 3 Study

Provided by Dow Jones

By Colin Kellaher 




  ATyr Pharma said a late-stage study of its lead clinical program didn't meet its main goal. 



  ATyr on Monday said the Phase 3 study of efzofitimod in the interstitial lung disease pulmonary sarcoidosis missed its primary endpoint of change from baseline in daily steroid doses at 48 weeks. 



  The San Diego clinical-stage biotechnology company said it believes drug activity for efzofitimod was evidenced by improvements across multiple clinically relevant efficacy endpoints, and that it plans to engage with the U.S. Food and Drug Administration to review the study results and determine the path forward for efzofitimod in pulmonary sarcoidosis. 



  ATyr is also investigating efzofitimod in a Phase 2 study in patients with systemic sclerosis-related interstitial lung disease. 



  Trading in shares of aTyr, which closed Friday at $6.03, was halted premarket on Monday. 





  Write to Colin Kellaher at colin.kellaher@wsj.com 





  (END) Dow Jones Newswires



  September 15, 2025 08:06 ET (12:06 GMT)


Copyright (c) 2025 Dow Jones & Company, Inc.
  

					The articles, information, and content displayed on this webpage may
					include materials prepared and provided by third parties. Such
					third-party content is offered for informational purposes only and
					is not endorsed, reviewed, or verified by Morningstar.
				
 

					Morningstar makes no representations or warranties regarding the
					accuracy, completeness, timeliness, or reliability of any third-party
					content displayed on this site. The views and opinions expressed in
					third-party content are those of the respective authors and do not
					necessarily reflect the views of Morningstar, its affiliates, or employees.
				
 

					Morningstar is not responsible for any errors, omissions, or delays
					in this content, nor for any actions taken in reliance thereon.
					Users are advised to exercise their own judgment and seek independent
					financial advice before making any decisions based on such content.
					The third-party providers of this content are not affiliated with
					Morningstar, and their inclusion on this site does not imply any
					form of partnership, agency, or endorsement.
				
 

				Popular
				
 
  
 
 
 
 
3 Stocks to Sell and 3 Stocks to Buy for October
 
Plus, lessons from September’s stock market activity. 
 
 
David Sekera, CFA and Susan Dziubinski 
 
 
 
14 Elite Funds and ETFs, and 5 Popular Funds That Just Missed the Mark
 
Russ Kinnel shares investment ideas from his annual Thrilling Funds list and discusses how he screens for quality investments in a sea of options. 
 
 
Russel Kinnel and Ivanna Hampton 
 
 
 
The 10 Best Companies to Invest in Now
 
The stocks of these high-quality companies look cheap today. 
 
 
Tori Brovet 
 
 
 
10 Top-Performing US Dividend Stocks
 
Chevron and Pfizer are among Q3's high-yielding winners. 
 
 
Bella Albrecht 
 
 
 
9 New 5-Star Stocks This Week
 
Deutsche Telekom and Mondelez are now seen as significantly undervalued. 
 
 
Bella Albrecht 
 
 
 
 

			Sponsor Center